Brokers Issue Forecasts for AbbVie FY2026 Earnings

AbbVie Inc. (NYSE:ABBVFree Report) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for AbbVie in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould anticipates that the company will post earnings per share of $14.12 for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $210.00 target price on the stock. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

AbbVie (NYSE:ABBVGet Free Report) last announced its earnings results on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. During the same quarter last year, the firm earned $2.31 earnings per share. AbbVie’s quarterly revenue was up 8.4% on a year-over-year basis.

Other equities analysts also recently issued research reports about the stock. Bank of America lifted their target price on shares of AbbVie to $204.00 and gave the stock a “hold” rating in a research note on Monday. Erste Group Bank raised shares of AbbVie to a “strong-buy” rating in a research note on Monday, March 17th. Morgan Stanley lifted their target price on shares of AbbVie from $241.00 to $250.00 and gave the stock an “overweight” rating in a research note on Monday, April 28th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Finally, Citigroup lifted their target price on shares of AbbVie to $205.00 and gave the stock a “hold” rating in a research note on Wednesday. Eight research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $211.29.

Get Our Latest Stock Analysis on ABBV

AbbVie Price Performance

Shares of NYSE ABBV opened at $191.27 on Tuesday. AbbVie has a twelve month low of $163.52 and a twelve month high of $218.66. The firm has a fifty day simple moving average of $183.78 and a 200 day simple moving average of $187.32. The company has a market capitalization of $337.86 billion, a PE ratio of 79.70, a P/E/G ratio of 1.62 and a beta of 0.50. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. eCIO Inc. acquired a new position in shares of AbbVie during the first quarter valued at about $182,000. Militia Capital Partners LP purchased a new position in AbbVie during the first quarter worth about $126,000. CBIZ Investment Advisory Services LLC boosted its holdings in AbbVie by 8.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 1,006 shares of the company’s stock worth $211,000 after purchasing an additional 79 shares during the last quarter. Invst LLC boosted its holdings in AbbVie by 68.9% during the first quarter. Invst LLC now owns 6,454 shares of the company’s stock worth $1,352,000 after purchasing an additional 2,633 shares during the last quarter. Finally, Modern Wealth Management LLC boosted its holdings in AbbVie by 9.4% during the first quarter. Modern Wealth Management LLC now owns 52,808 shares of the company’s stock worth $11,064,000 after purchasing an additional 4,544 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of AbbVie stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the completion of the transaction, the executive vice president now directly owns 53,234 shares in the company, valued at $11,183,398.72. This trade represents a 52.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.25% of the company’s stock.

AbbVie Company Profile

(Get Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read More

Earnings History and Estimates for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.